| 2026-03-16 |
详情>>
内部人交易：
Hartley Lindsey Marie等共交易8笔
|
| 2026-02-24 |
详情>>
股本变动：
变动后总股本5189.77万股
|
| 2026-02-24 |
详情>>
业绩披露：
2025年年报每股收益-0.34美元,归母净利润-1570.3万美元,同比去年增长-57.6%
|
| 2026-02-24 |
财报披露：
美东时间 2026-02-24 盘前发布财报
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.06美元,归母净利润-254.7万美元,同比去年增长75.54%
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-0.07美元,归母净利润-325.5万美元,同比去年增长61.96%
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.08美元,归母净利润-383.4万美元,同比去年增长42.22%
|
| 2025-04-30 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.To elect eight members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2025;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
4.To approve the Axogen, Inc. Fourth Amended and Restated 2019 Long-Term Incentive Plan (the "A&R 2019 Plan") to increase the number of shares authorized for issuance thereunder from 10,500,000 to 13,400,000;
5.To recommend, in a non-binding vote, the frequency of future non-binding shareholders' votes to approve the compensation of the Company’s named executive officers;
6.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2025-02-26 |
详情>>
业绩披露：
2022年年报每股收益-0.69美元,归母净利润-2894.8万美元,同比去年增长-7.27%
|
| 2025-02-26 |
详情>>
业绩披露：
2024年年报每股收益-0.23美元,归母净利润-996.4万美元,同比去年增长54.12%
|
| 2024-11-07 |
复牌提示：
2024-11-07 09:33:32 停牌，复牌日期 2024-11-07 09:38:32
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.24美元,归母净利润-1041.4万美元,同比去年增长41.57%
|
| 2024-11-07 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.42美元,归母净利润-1782.3万美元,同比去年增长24.26%
|
| 2024-08-08 |
详情>>
业绩披露：
2024年中报每股收益-0.2美元,归母净利润-855.6万美元,同比去年增长37.70%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.15美元,归母净利润-663.5万美元,同比去年增长6.21%
|
| 2024-04-24 |
股东大会：
将于2024-06-05召开股东大会
会议内容 ▼▲
- 1.To elect nine members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2024;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
4.To approve the Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan (the "A&R 2019 Plan") to increase the number of shares authorized for issuance thereunder from 8,000,000 to 10,500,000;
5.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2024-03-05 |
详情>>
业绩披露：
2023年年报每股收益-0.51美元,归母净利润-2171.6万美元,同比去年增长24.98%
|
| 2023-07-07 |
股东大会：
将于2023-08-15召开股东大会
会议内容 ▼▲
- 1. To elect nine members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2023;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
4.To approve the Axogen, Inc. Third Amended and Restated 2019 Long-Term Incentive Plan (the “A&R 2019 Plan”) to increase the number of shares authorized for issuance thereunder from 8,000,000 to 10,500,000;
5.To approve the Axogen, Inc. Amended and Restated 2017 Employee Stock Purchase Plan (the "A&R 2017 ESPP") to increase the number of shares authorized for issuance thereunder from 600,000 to 1,200,000;
6.To approve an amendment to the Axogen, Inc. Amended and Restated Bylaws to set the range of the number of directors on our Board of Directors to be between 7 to 11 members and allow our Board of Directors to set the specific number of directors within the range;
7.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2022-04-14 |
股东大会：
将于2022-05-25召开股东大会
会议内容 ▼▲
- 1.To elect eight members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2022;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
4.To approve the Axogen, Inc. Second Amended and Restated 2019 Long-Term Incentive Plan (the “A&R 2019 Plan”);
5.To approve an amendment to the Axogen, Inc. Amended and Restated Bylaws to allow our Board of Directors to determine the number of directors;
6.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-31 |
股东大会：
将于2021-05-10召开股东大会
会议内容 ▼▲
- 1.To elect eight members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2021;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
4.To approve the Axogen, Inc. Amended and Restated 2019 Long-Term Incentive Plan (the “A&R 2019 Plan”);
5.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2020-04-17 |
股东大会：
将于2020-05-28召开股东大会
会议内容 ▼▲
- 1.To elect eight members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2020;
3.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement
4.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2019-06-27 |
股东大会：
将于2019-08-14召开股东大会
会议内容 ▼▲
- 1.To elect eight members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To approve the Axogen, Inc. 2019 Long Term Incentive Plan;
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2019;
4.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
5.To recommend by a non-binding advisory vote the frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers;
6.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2018-03-29 |
股东大会：
将于2018-05-14召开股东大会
会议内容 ▼▲
- 1.To elect seven members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To approve the amendment and restatement of the Amended and Restated Articles of Incorporation of the Company in the form of Appendix A hereto to increase the authorized shares of common stock of the Company from 50,000,000 to 100,000,000 shares and change the address of the Company’s Registered Office;
3.To ratify the selection of Deloitte & Touche LLP as our independent registered public accounting firm for the year ending December 31, 2018;
4.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2017-04-07 |
股东大会：
将于2017-05-24召开股东大会
会议内容 ▼▲
- 1.To elect seven members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To approve an amendment and restatement of the AxoGen, Inc. 2010 Stock Incentive Plan (as amended and restated on September 27, 2011, May 13, 2014 and May 26, 2016 (the “2010 Plan”) to: (i) increase the number of shares of common stock of AxoGen authorized for issuance under the 2010 Plan from 5,500,000 to 7,700,000, and (ii) make certain administrative changes to the 2010 Plan (the 2010 Plan as amended and restated, the “A&R 2010 Plan”);
3.To approve the AxoGen, Inc. 2017 Employee Stock Purchase Plan;
4.To ratify the selection of Lurie, LLP as our independent registered public accounting firm for the year ending December 31, 2017;
5.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|
| 2016-04-08 |
股东大会：
将于2016-05-26召开股东大会
会议内容 ▼▲
- 1.To elect seven members to our board of directors (the “Board of Directors”) to hold office for the ensuing year and until their successors are elected and qualified;
2.To approve an amendment and restatement of the AxoGen, Inc. 2010 Stock Incentive Plan (as amended and restated on September 27, 2011 and May 13, 2014 (the “2010 Plan”)) (the “A&R 2010 Plan”) to: (i) increase the number of shares of common stock of AxoGen authorized for issuance under the plan from 3,500,000 to 5,500,000, (ii) to approve the award limits and other terms applicable to awards intended to qualify as “performance-based compensation” for purposes of Section 162(m) of the Internal Revenue Code of 1986, as amended, (iii) extend the duration of the plan to 2026, and (iv) make certain administrative changes to the 2010 Plan;
3.To ratify the selection of Lurie, LLP as our independent registered public accounting firm for the year ending December 31, 2016;
4.To approve, on a non-binding advisory basis, the compensation of the Company’s named executive officers as disclosed in the Company’s Proxy Statement;
5.To recommend by a non-binding advisory vote the frequency of future non-binding advisory votes on the compensation of the Company’s named executive officers; 6.To consider and act upon any other matters that may properly come before the Meeting or any adjournment or postponement thereof.
|